<DOC>
	<DOCNO>NCT00370422</DOCNO>
	<brief_summary>The purpose study compare efficacy safety intravitreal injection bevacizumab alone versus bevacizumab combine triamcinolone treatment refractory diabetic macular edema .</brief_summary>
	<brief_title>Bevacizumab Versus Combined Bevacizumab Triamcinolone Refractory Diabetic Macular Edema ; Randomized Clinical Trial</brief_title>
	<detailed_description>According early treatment diabetic retinopathy study ( ETDRS ) , treatment choice diabetic macular edema laser therapy , may neither effective curative patient . Corticosteroids may beneficial effect diabetic macular edema . Other newly introduce medication macular edematous lesion anti-VEGF vascular endothelial growth factor ) drug . In randomized , sham-controlled , multicenter , three-arm clinical trial , try evaluate safety efficacy intravitreal bevacizumab alone combination intravitreal triamcinolone treatment refractory diabetic macular edema .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Cases clinically significant macular edema ( CSME ) persistent retinal thicken initial supplemental macular photocoagulation Monocularity , History vitrectomy , Glaucoma ocular hypertension , Significant medium opacity , Existence traction macula</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Cystoid macular edema</keyword>
	<keyword>Diabetic macular edema</keyword>
	<keyword>Hard exudate</keyword>
	<keyword>Intravitreal bevacizumab</keyword>
	<keyword>Intravitreal triamcinolone</keyword>
	<keyword>Macular thickness</keyword>
</DOC>